Wire · opportunities
FDA Approves sNDA for Taletrectinib in ROS1+ NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The US FDA approved a supplemental New Drug Application for taletrectinib (Ibtrozi) in ROS1-positive non-small cell lung cancer, updating the label with extended duration of response data showing nearly 50 months median benefit in TKI-naïve patients. The approval precedes the PDUFA target and incorporates results from ongoing TRUST clinical trials, reinforcing taletrectinib as a potent, CNS-active next-generation ROS1 inhibitor with a consistent safety profile.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 17 Sep 2026 and 18 Sep 2026.
◆ ◆ The Wire takeaway
You must update your oncology or biotech positioning to highlight taletrectinib's new long-term efficacy label for ROS1+ lung cancer in the US. Early regulatory wins like this open clinical pathways and signal patient demand shifts that biotech founders can capitalise on.
◆ Coverage
6 sources · first reported 17 Sep 2026 · latest 18 Sep 2026
◆ Related on Wire
◆ Topics